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Depression in Parkinson’s Disease (PD) is a prevalent and invalidating symptom. Deep
brain stimulation (DBS) allows for an improvement of PD motor features, but its effects
on mood are difficult to predict. Here, we review the evidence regarding mood effects
after DBS of either subthalamic nucleus (STN) or globus pallidus pars interna (GPi).
Different influences of multiple factors contribute to impact the neuropsychiatric outcome
after surgery. Psychosocial presurgical situation, postsurgical coping mechanisms,
dopaminergic treatment modifications, and direct effects of the stimulation of either target
are all playing a distinct role on the psychological well-being of patients undergoing DBS.
No clear advantage of either target (STN vs. GPi) has been consistently found, both
being effective and with a favorable profile on depression symptoms. However, specific
patients’ characteristics or anatomical considerations can guide the neurosurgeon in the
target choice. Further research together with technological advances are expected to
confine the stimulation area within dysfunctional circuits causing motor symptoms of PD.
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DEPRESSION AND PARKINSON’S DISEASE (PD)
Depression in PD is a common finding, and has an important impact on patient’s quality of
life (QoL) (1). Published prevalence estimates vary depending on the population studied, but
significant depressive symptoms occur in around 35% of patients (2). The impact of depression
on patients’ well-being can hardly be overestimated. It appears to be more distressing for patients
and their families than motor symptoms (3). Treating depression have beneficial effects also on
motor performance (4) and conversely depressive symptoms are among the stronger predictors of
initiation of dopaminergic therapy (5).
While depression is among the most common non-motor symptoms of PD, its pathophysiology
is incompletely understood. As in any chronic illness, a reactive depression is observed after
the diagnosis is communicated to the patient, related to fears about PD and actual or perceived
disability. However, mood symptoms tend to occur 4–6 years before the motor symptoms, and
most often predate the established diagnosis, indicating that neurobiological factors are more
determinant than psychosocial ones (6). According to the Braak hypothesis (7), alfa-synuclein
deposition and corresponding neurodegeneration in PD begins in non-dopaminergic brainstem
structures, including locus coeruleus and raphe nucleus. A decrease of endogenous production
of serotonin have been documented both post-mortem (8) and in-vivo (9), supporting the notion
of an organic origin to depression in PD. The involvement of other neurotransmitters, including
noradrenaline and dopamine, is testified by the positive effects on mood of dopamine agonists
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and stimulants such as methylphenidate (10, 11). Further,
multiple neuroimaging studies describe anatomical and
functional differences among PD patients with depression and
without depression: the most consistent evidence shows reduced
activity and possibly gray matter density in the frontal lobe and
other limbic cortical and subcortical structures (12).
MOOD IMPACT OF DBS
The surgery for DBS most often follows a long path of physical
deterioration as a consequence of advancing PD. From the
patient’s perspective, the decision to accept such an invasive
procedure is often a difficult one, carefully pondered, sometimes
perceived as a last resort before losing an acceptable quality
of life. It is rightfully considered a major event by patients.
Even if they are duly and fully informed about the limitations
of DBS, the procedure is often accompanied by exaggerated
expectations, that match the (overestimated) perceived surgical
risk. As a consequence, patients might fail to cope with the
numerous hurdles they may encounter after the surgery. One
of these hurdles is represented by the important modifications
in familial and social relationships, that occur as a result of the
overall improvement of the motor symptoms. Family members
and caregivers might interpret the striking reduction of tremor
and dyskinesias as the relieving end of their relative’s need
for care, after they underwent the “miraculous” surgery. On
the other side, the patient could suddenly loose his “disease
label” that had become part of his own identity, and informed
most of his social relationships. Hindrances from non-motor
symptoms are often not adequately recognized and understood
by caregivers. Couples can be particularly put at strain: after
years of daily routine revolving around the medication timetable,
the anticipation of motor fluctuations and dyskinesias, major
changes can intervene, and modify intensely bonding dynamics,
centered on the disease (13–15).
Accounting for these social and psychological factors is of the
highest importance during the pre-operative evaluation for DBS,
and must be included in the multidisciplinary team discussions.
In general, the DBS procedure has a positive effect on mood
aggregate scales, independently from the chosen target (16, 17);
this was confirmed by a recent meta-analysis, which found a
small and moderate reduction in depression symptoms after
STN-DBS or GPi-DBS, respectively (18). Interestingly, there
is an important heterogeneity in the observed pre vs. post-
surgical modifications in depression scores, which seems to be
modulated by two related factors: disease duration and UPDRS
score. Perhaps not surprisingly, the greater benefit on depression
scores was observed in those patients who had endured PD for
more years, and suffered from a greater functional impairment. It
must be underscored however, that depression severity scores do
not necessarily correlate with these two factors. A more plausible
interpretation stemming from this meta-analysis is that when
the disease is advanced the dramatic improvement of motor
symptoms and levodopa complications after DBS has a notable
effect on depression symptoms, independently from the starting
depression severity.
The effects of DBS on brain neurochemistry (including
dopaminergic and non-dopaminergic systems) is an interesting
topic of investigation, still insufficiently explored: rodent
experiments suggest that DBS might in part act by modulating
5HT and NA release. An influence of DBS on limbic
circuits mediated by indirect neurotransmitter release cannot be
excluded (19, 20).
STN-DBS Effects on Mood
STN is themost frequently used target for DBS. Its positive effects
are broad and include tremor, rigidity, bradykinesia reduction,
but also gait and balance improvement, when levodopa sensitive.
Even if the effects on mood have been quite extensively
studied, the literature reports conflicting results, probably due
to differences in cohorts or assessment methods. Early reports
found a relatively high risk of suicide among patients treated
by DBS (21–24), mostly (although not only) in patients with
a previous depression history. The absolute numbers of post-
operative suicides qualify it as a rare event, and as such the
cohorts are underpowered to conclude for an actual increase
of suicides or suicidal ideation among STN-DBS patients.
Moreover, multiple and diverse factors can play a role in the
observed apparent increase of the suicide rate. Among others,
a selection bias could exist, so that patients least accepting their
disease are more willing to undergo DBS. This population would
be more prone to disappointment when DBS fails to meet their
expectations. Expectations should not be unrealistic, and the role
of the caring team is to assure that patients fully understand the
risks and the likely benefits from DBS, particularly underscoring
that DBS will not stop the neurodegenerative disease to progress.
In face of these early findings, the formal assessment of
depressive symptoms showed positive effects of STN-DBS
(25–28). The outcome on mood symptoms is highly variable and
likely depends on multiple factors, that underscore how patient’s
selection is crucial for a positive outcome (29).
Dopamine-Withdrawal Syndrome
STN-DBS allows for an important reduction of dopaminergic
medication, if not for a complete withdrawal. Neuronal
degeneration in PD involves also mesolimbic dopaminergic cells
in the ventral tegmental area, which project to ventral striatum
and orbito-frontal regions that are involved in non-motor
functions, which are central in the brain circuitry of motivation
and reward. It is widely believed that a complete interruption
of dopaminergic medication, even if allowed from a motor
point of view, can be responsible for the progressive appearance
of a postoperative apathy and anhedonia, and eventually to
the appearance or worsening of depressive symptoms (25, 30).
This crucial aspect must be considered during the early and
delayed postoperative phase, as apathy and its consequences
can appear slowly and progressively. Their correct assessment
and management can prevent depressive states and ultimately
improve the overall outcome of STN-DBS (30, 31).
The direct induction of neuropsychiatric symptoms
by STN-DBS is well documented, particularly for the
induction of hypomanic or manic states, which can be
reversed by modifying the stimulation parameters. These
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effects are thought to arise following the stimulation of
sub-areas of the STN involved in limbic circuits, as first
suggested by Krack et al. after observing a stimulation-
induced “mirthful laughter” reaction (32). Multiple lines
of evidence document the existence of a functional
specialization within the STN, and basal ganglia structures
in general (33–37).
Cortico-subcortico-cortical loops seem to maintain a certain
degree of functional segregation within each node, by which sub-
areas within each structure can be identified as preferentially
connected to cortical and subcortical regions processing similar
information. Within this general principle of organization, the
STN seem to play a pivotal role, and host the integration
of different functional circuits (34). The posterior-dorsal STN
is the target of DBS for PD, as it is thought to be
a node of the motor circuit (with an overall antikinetic
function). More anteriorly and ventrally however, the STN
has a stronger connectivity with cortical areas involved
in cognitive and emotional (“limbic”) functions (38): this
is considered as being the anatomical substrate underlying
undesired neuropsychiatric effects of DBS. The induction
of hypomanic states has been reported most consistently
following ventral STN stimulation: patients suffer from an
excited hyperactivity, reduce their sleep time, engage in reward-
seeking behaviors including unnecessary buying, with heavy
consequences on familial or working relationships. The fact
that these behavioral disturbances can be promptly reversed
by modifying stimulation parameters, supports the notion of
a direct role of the stimulation of non-motor STN subareas.
The most effective management of hypomanic manifestations
imply shifting the stimulation to more dorsal contacts,
bringing indirect evidence on the ventral location of the
“limbic” STN.
GPI vs. STN-DBS Mood Effects
The globus pallidus internus (GPi) has been used as a stimulation
target for Parkinson’s Disease since the early days of DBS,
due to its recognized benefits on motor symptoms (39, 40).
However, STN has been consistently considered the preferred
target, based on evidence from early trials not specifically
designed (41) or weighted (42) for a comparison among
the two stimulation targets. Eventually, most centers have
been proposing almost exclusively STN as a DBS target for
advanced PD, resulting in an accumulation of knowledge on
the benefits and side effects of STN stimulation, leaving GPi-
DBS comparatively less investigated. As an end result, less
evidence is available about the psychiatric effects of GPi-DBS
in PD. Some early assumptions—while possibly correct—have
skewed patient selection, further propagating the publication
bias. Most recently, at least three randomized clinical trials
comparing GPi to STN have been conducted, specifically
addressing the differential therapeutic profiles of the two
stimulation targets (16, 43, 44). The trials are substantially
concordant in describing a similar benefit on motor symptoms
from DBS of either stimulation target. When analyzing motor
sub scores however, some slight differences emerge—mostly
with no statistical significance—and might be considered in
the pre-implantatory phase. Among the cardinal PD motor
features, rigidity, and bradykinesia could possibly respond better
to STN than GPi stimulation; levodopa responsive gait and
balance issues appeared to improve better with GPi stimulation
in one of the trials, which also showed a trend toward more
pronounced and sustained dyskinesias reduction after GPi than
STN stimulation (45). All trials show a greater medication
reduction after STN than GPi-DBS, which is sustained at 3 years
follow-up (46).
Regarding neuropsychiatric effects, GPi-DBS seems to have
a lesser impact than STN-DBS (45). This notion however
is based on a limited number of well-conducted trials, and
some confounding factors have to be taken in consideration.
For instance, Anderson et al report early post-operatory
anxiety as being more frequent after STN-DBS (47), a
group in which medication reduction was more abrupt
and important. A dopaminergic-withdrawal syndrome (30)
could therefore be held responsible, and could have been
prevented by slowly tapering down the medication (48).
The COMPARE trial (16) assessed mood disorders through
the Visual Analog Mood Score (VAMS), and did not find
differences among STN and GPi in the compound score.
However, the item “angry” was higher for the STN-operated
patients. This was observed as well by Weintraub (49),
who describe that “GPi patients were happier, less angry
or bitter and less tired compared with STN patients.” In
the same publication, authors could not confirm a higher
risk of suicide among DBS patients, either implanted in the
STN or GPi.
MANAGEMENT OF DEPRESSION IN THE
PREOPERATIVE AND POSTOPERATIVE
PHASES
The existence of depressive symptoms is not per se a
contraindication to DBS surgery. However, ongoing severe
depression, psychotic symptoms, and suicidal ideation should be
considered absolute contraindications as they might worsen and
increase suicidal risk, particularly in the first year after surgery
(50–52). Less evidence is available regarding severe depressive
patients who were eventually stabilized by psychotherapy and
medication, months or years prior to undergoing DBS: a trend
toward a slightly worse motor and mood outcome has been
described, but this certainly does not constitute an absolute
contraindication to surgery (53). In any case, most groups
and guidelines support the recommendation of a thorough
psychiatric assessment before DBS surgery, and of a careful
post-operative follow-up. Of note, the post-operative psychiatric
assessment should not be limited to the immediate post-
operative period, as the occurrence of apathy, for instance,
peaks at around 4 months after surgery, often accompanied by
depressive symptoms (30). Particularly after STN-DBS, which
allows for a steeper reduction of dopaminergic medication,
dopamine withdrawal symptoms should be prevented, when
possible favoring the continued treatment with dopamine
agonists (31).
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NEUROANATOMICAL AND
NEUROSURGICAL CONSIDERATIONS
The advent of DBS has offered an unprecedented opportunity
for in-vivo investigation of the functional organization of basal
ganglia. This knowledge has been growing together with clinical
observations on patients undergoing DBS, and has driven
further the development and the refining of this remarkable
neuromodulation treatment. The occurrence of cognitive,
behavioral and mood effects after DBS have been key in updating
models of basal ganglia functioning, that help now predict the
outcome of the procedure. From a neuroanatomic point of view,
the large spectrum of effects observed after DBS confirmed
some previous notions on the basal ganglia organization, but
also exposed the limits of excessively schematizing models. The
most influential model of basal ganglia organization (54, 55)
proposed the existence of strictly segregated cortico-subcortico-
cortical loops, each originating and terminating in distinct
prefrontal cortical areas. Accordingly, circuits processing motor,
cognitive, and emotional information would be kept segregated
in basal ganglia nuclei, within subareas with a specific functional
specialization. Accumulating evidence strongly suggests that
there is substantial overlap of functional subareas, underpinning
information exchange and integration (33, 34, 36, 38). This
might partially explain the rich interaction among mood and
motor symptoms (5) in PD, and most likely the occurrence
of hypomanic manifestations after stimulation of dorso-lateral
STN, which is considered as having a predominant motor
function (25, 56). The distribution of cortico-STN projections
in the primate (38) and human brain [as studied by DTI MRI-
tractography (33, 34)] suggests that wrong positioning of the
stimulating contact is not necessary tomodulate non-motor parts
of STN (57). Nevertheless, several studies were able to show that
patients presenting postoperative hypomania were stimulated too
ventrally, mostly within the anatomically defined limbic STN
(56–58), and that shifting stimulation tomore dorsal contacts was
effective in reducing the neuropsychiatric symptoms.
The GPi is also involved in multiple non-motor functions,
and probably has a topographical organization mirroring what
observed in STN, with an antero-posterior and ventro-dorsal
gradient of connectivity (limbic->associative->motor). This has
been demonstrated thanks to tracing experiments in non-human
primates (59), confirmed in DTI imaging studies (60). It must
be underscored however that GPi does not receive direct cortical
inputs; this parcellation is based mainly on the distribution of
connections to striatum. Therefore, the exact topography of GPi
sub territories is less clear than for the STN. Nevertheless, the
relative volume of the motor GPi to be targeted by DBS, is
definitely greater than the motor STN. Therefore, the probability
of stimulating current spreading to non-motor territories is
probably lower (16). In that respect, this might represent an
advantage of the GPi over the STNwhen choosing the stimulating
target based on the theoretical risk of non-motor undesired
side effects.
The advent of segmented (directional) electrodes have
shown to increase the therapeutic window for controlling
motor symptoms (61, 62). This new technology provides
a unique opportunity to investigate and refine anatomo-
clinical correlations for non-motor symptoms as well, as these
investigations can be performed not only in the vertical plane (Z
axis), but also in the horizontal plane (X and Y axes). A better
localization of non-motor areas in the STN should prevent the
appearance of related symptoms. Recent advances in so-called
“adaptive stimulation” are also promising in reducing undesired
DBS side effects related to stimulation of non-motor STN (or
GPi) areas. Based on recorded neurophysiological activity, the
stimulation intervenes only when detecting neurophysiological
activity linked with the motor akinesia, and delivers an
intermittent stimulation tailored on patients’ needs (63, 64).
CONCLUDING REMARKS
Careful patient selection, an experienced neurosurgeon, and
adequate peri-operative management of mood disturbances
make DBS a safe treatment in terms of expected neuropsychiatric
outcomes. A causative role for the stimulation in triggering or
worsening psychiatric diseases appear unlikely, which is overall
reassuring. Hence, there is insufficient evidence to conclude for
an advantage of a stimulation target solely based on the expected
effects on depressive symptoms. We do recommend however to
carefully assess the neuropsychiatric profile of each patient and
let it inform the decisional process when considering both STN
and GPi as stimulation targets. Specific preoperative symptoms
(apathy, bipolar traits, anxiety, dopamine dysregulation
syndrome among others) could tilt the balance toward any of the
two targets, possibly improving DBS outcome for a given patient.
Further technological advances are expected to improve surgical
targeting and optimize stimulation methods, allowing for a
timely modulation restricted to the dysfunctional circuits causing
PD symptoms.
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